…ong ICS users, FF was associated with fewer clinically detected COVID-19 events than BUD (adjusted HR 0.12, 95% CI 0.02 to 0.73; crude 6…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsPopular entities in these results
Choose an entity to see the articles in which it was identified.
Matching articles
29,499 articles · page 229 of 2459…ommon and severe infection, with a 90-day mortality of 24%–32%. Cloxacillin is regarded as a first-line antibiotic treatment in SAB in Swed…
…graphic characteristics.Results There were 4.83 million overall PPH in 2023, an overall rate of 180.9 per 10 000 JKN enrolees (acut…
…from real-world clinical practice (RWE) remains limited.Methods Adalimumab vs Ixekizumab Real-world Effectiveness is a multicentre cohort …
…ed factors in patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA).Methods This cross-sectional analysis used data from the …
…olerability, pharmacokinetics (PK) and pharmacodynamics (PD) of bepranemab.Methods UP0047 ( NCT03464227) and UP0065 (NCT03605082) were pha…
…Objective This study evaluates whether Taiwan’s national oral cancer screening programme, implemented in 1999, has led to a reductio…
… in group 3, 23% in group 4, 20% in group 5 and 68% in group 6. Nystagmus was observed in 0.8%, 0.4%, 1.8%, 2.6%, 5.0% and 47% in the res…
…as agonists at serotonin 5-HT2A receptors in the brain, include psilocybin, 5-methoxydimethyltryptamine, and N,N-dimethyltryptamine (trypt…
…itors (PCSK9 inhibitors), including evolocumab, alirocumab, and inclisiran, are potent lipid-lowering agents indicated for patients at hig…
…nificant difference in mean bodyweight was found between groups.Nivolumab was administered to 108 patients: 64 (weight 62.29 ± 32.06kg) r…
…Background and Importance Bacterial eye infections at tertiary hospitals pose serious health challenges and requir…